For metastatic breast cancer patients, it has been reported that the vast majority (>90%) of patients shed detectable levels of ctDNA into the blood circulation [29], indicating that plasma-based analysis could be a suitable approach for AKT1 E17K mutation detection in this patient population. This evidence concerns the gene AKT1 and breast cancer.